Katairo GmbH, a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for back of the eye diseases, today announced topline results of the STARTT study. The Stargardt Remofuscin Treatment Trial (STARTT) was a 2-year study comparing Remofuscin® tablets to placebo. The primary endpoint, quantitative autofluorescence (qAF), a novel method to quantify retinal autofluorescence, […]